Breast Cancer Clinical Trials in Salt Lake City, Utah

21 studies are recruiting for breast cancer in Salt Lake City, Utah right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

    The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Utah Cancer Specialists, Salt Lake City, Utah
    Locations
    567 in total
    Run by
    Stemline Therapeutics, Inc.

    See if you can join NCT06492616 on ClinicalTrials.gov

  2. A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

    The purpose of this study is to assess the safety of GDC-4198 alone and in combination with giredestrant and also the efficacy of GDC-4198 + giredestrant versus abemaciclib + giredestrant in participants with locally advanced or metastatic ER+, HER2- breast cancer. The study consists of 2 phases: P…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Utah Huntsman Cancer Institute, Salt Lake City, Utah
    Locations
    64 in total
    Run by
    Genentech, Inc.

    See if you can join NCT07100106 on ClinicalTrials.gov

  3. A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

    This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participants with endocrine-sensitive PIK3CA-mutated hormone receptor-p…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Huntsman Cancer Hospital at the University of Utah, Salt Lake City, Utah
    Locations
    241 in total
    Run by
    Hoffmann-La Roche

    See if you can join NCT06790693 on ClinicalTrials.gov

  4. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

    This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
    Locations
    231 in total
    Run by
    Relay Therapeutics, Inc.

    See if you can join NCT06982521 on ClinicalTrials.gov

  5. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with es…

    Stage
    Phase 3
    Ages
    18 to 60
    Site
    University of Utah Sugarhouse Health Center, Salt Lake City, Utah
    Locations
    1261 in total
    Run by
    NRG Oncology

    See if you can join NCT05879926 on ClinicalTrials.gov

  6. A Phase 1 Study of LNCB74 in Advanced Solid Tumors

    This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Intermountain/LDS Hospital Ph 1 Research Program, Salt Lake City, Utah
    Locations
    14 in total
    Run by
    NextCure, Inc.

    See if you can join NCT06774963 on ClinicalTrials.gov

  7. Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

    This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Clinical Trial Site, Salt Lake City, Utah
    Locations
    181 in total
    Run by
    Olema Pharmaceuticals, Inc.

    See if you can join NCT07085767 on ClinicalTrials.gov

  8. Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

    This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have completed both neoadjuvant and postoperative adjuvant standard of car…

    Stage
    Phase 3
    Ages
    18 to 100
    Site
    University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah
    Locations
    179 in total
    Run by
    Greenwich LifeSciences, Inc.

    See if you can join NCT05232916 on ClinicalTrials.gov

  9. A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

    A Study of Emi-Le in Participants with Solid Tumors

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Huntsman Cancer Institute, Salt Lake City, Utah
    Locations
    26 in total
    Run by
    Day One Biopharmaceuticals, Inc.

    See if you can join NCT05377996 on ClinicalTrials.gov

  10. I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic res…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
    Locations
    42 in total
    Run by
    QuantumLeap Healthcare Collaborative

    See if you can join NCT01042379 on ClinicalTrials.gov

  11. A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

    The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Huntsman Cancer Institute, Salt Lake City, Utah
    Locations
    202 in total
    Run by
    Pfizer

    See if you can join NCT07062965 on ClinicalTrials.gov

  12. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

    This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    START Center for Cancer Care - Mountain Region, Salt Lake City, Utah
    Locations
    14 in total
    Run by
    858 Therapeutics, Inc.

    See if you can join NCT06395519 on ClinicalTrials.gov

  13. Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System

    This is an open-label, single arm, single center, non-randomized feasibility study of the Muse MRgFUS System in subjects with breast cancer. Subjects will undergo partial ablation of half (≤50%) of one of their tumors (if multifocal or multicentric disease) followed by surgical resection per standa…

    Stage
    EARLY_Phase 1
    Ages
    18 and older
    Site
    Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah
    Run by
    University of Utah

    See if you can join NCT05291507 on ClinicalTrials.gov

  14. Improving Care for Rural Patients With Solid Tumors

    This study will assess if the CARES (Cancer Advocacy, Resources, Education and Support) intervention improves time to start of treatment after diagnosis and time to treatment completion for solid tumors (ex: lung, head, neck, thyroid, cervical, breast, bladder, colon, and rectal cancers) in rural p…

    Stage
    Not phased
    Ages
    18 to 99
    Site
    Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah
    Locations
    14 in total
    Run by
    University of Colorado, Denver

    See if you can join NCT04916990 on ClinicalTrials.gov

  15. 5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer

    The goal of this study is to evaluate 5 days vs. 9 days of whole breast radiation.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
    Run by
    University of Utah

    See if you can join NCT06961955 on ClinicalTrials.gov

  16. SAVE Trial: SAfe Opioid Use Video Education

    The study will assess the efficacy of a standardized postoperative patient-centered intervention designed to educate patients on the opioid epidemic, the judicious use of opioids, and the proper disposal of opioids. This trial is a single-institution, randomized controlled trial comparing total pos…

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of Utah Huntsman Cancer Institute, Salt Lake City, Utah
    Run by
    University of Utah

    See if you can join NCT07044583 on ClinicalTrials.gov

  17. Enhancing Mammography Programs for Outreach, Wellness, Education, and Resources (EMPOWER) in Underserved Populations Study

    This study is investigating the feasibility of a digital tool called a chatbot for providing educational information about mammography through a tablet, computer, or phone. This study will recruit participants who recently had a mammogram with the University of Utah. Based on their mammography resu…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Huntsman Cancer Institute/ University of Utah, Salt Lake City, Utah
    Run by
    University of Utah

    See if you can join NCT07029490 on ClinicalTrials.gov

  18. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Salt Lake City, Utah
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

  19. Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies

    The goal of this study is to assess the effect of brief mindfulness-guided meditations during radiation therapy (RT) for patients with anxiety related to RT for breast and gynecological cancers.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah
    Run by
    University of Utah

    See if you can join NCT07166042 on ClinicalTrials.gov

  20. First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

    This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, cataly…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Utah- Huntsman Cancer Center, Salt Lake City, Utah
    Locations
    37 in total
    Run by
    Relay Therapeutics, Inc.

    See if you can join NCT05216432 on ClinicalTrials.gov

  21. Community Services Navigation to Advance Health Equity in Breast Cancer Screening

    The goal of this study is to evaluate if adding community services navigation to the standard referral process for social needs is an effective and scalable strategy for addressing disparities in follow-up to abnormal breast cancer screening results. The investigators will determine the effectivene…

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of Utah Health Hospitals/Huntsman Cancer Institute Population Sciences, Salt Lake City, Utah
    Run by
    University of Utah

    See if you can join NCT06305312 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.